Riskpilot← Back to searchSign inGet full accessAdaptVac ApS
APSActiveCVR 38732730Nordre Fasanvej 215Research and experimental development on natural sciences and engineering · NACE 7210Est. 20178 employeeswww.adaptvac.com
Revenue 2024
DKK 8,4M
-88% vs 2023
EBITDA margin
35.3%
-95% vs 2023
Equity ratio
89.2%
Financial strength
Net profit 2024
DKK 1,7M
-97% vs 2023
| Revenue | DKK 8,4M | -88% |
| EBITDA | DKK 3M | -95% |
| Net profit | DKK 1,7M | -97% |
| Total assets | DKK 20M | -80% |
| Equity | DKK 17,9M | -70% |
| Employees | 8 | — |
Legal name
AdaptVac ApS
CVR number
38732730
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22. juni 2017
Share capital
DKK 50.000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør og en direktør i
forening eller af 4 medlemmer af bestyrelsen i forening.
Company purpose
Virksomhedens formål er at udvikle produkter og teknologi indenfor området vacciner og immunterapi samt hermed efter ledelsens skøn beslægtet virksomhed og serviceydelser.
Address
Nordre Fasanvej 215
Phone
+4526394649
Email
wdj@adaptvac.com
Website
www.adaptvac.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -406 | 432 | 1.417 | 20.231 | 1.331 | -1.582 | 69.205 | 8.393 |
| Staff expenses | -0 | -0 | -1.654 | -1.412 | -3.353 | -4.217 | -5.147 | -5.426 |
| EBITDA | -406 | 432 | -237 | 18.820 | -2.022 | -5.799 | 64.058 | 2.967 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -3 | -23 | -23 |
| EBIT | -406 | 432 | -237 | 18.820 | -2.022 | -5.802 | 64.035 | 2.944 |
| Net financials | -3 | -2 | -0 | -104 | -261 | -82 | 11 | -799 |
| Profit before tax | -409 | 430 | -237 | 18.715 | -2.283 | -5.884 | 64.047 | 2.145 |
| Tax | -89 | 97 | -52 | 3.255 | -501 | -1.089 | 13.161 | 430 |
| Net profit | -320 | 334 | -185 | 15.460 | -1.782 | -4.795 | 50.886 | 1.714 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 242 | 92 | 1.372 | 38.630 | 15.194 | 14.015 | 98.167 | 20.036 |
| Equity | -270 | 64 | -122 | 15.339 | 12.557 | 7.762 | 58.648 | 17.862 |
| Long-term debt | 0 | 0 | 70 | 172 | 0 | 0 | 0 | 0 |
| Short-term debt | 512 | 28 | 1.423 | 23.119 | 2.637 | 6.253 | 39.518 | 2.174 |
| Total debt | 512 | 28 | 1.494 | 23.291 | 2.637 | 6.253 | 39.518 | 2.174 |
EBITDA margin
35.3%
This company
15.8%
Market median
+123% vs market
20172024
Equity ratio
89.2%
This company
38.2%
Market median
+134% vs market
20172024
Return on equity
9.6%
This company
18.4%
Market median
-48% vs market
20172024
Net profit margin
20.4%
This company
8.1%
Market median
+152% vs market
20172024
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
20172024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20172024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-06-22 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
WA Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
AF Management | Management | 2017 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NextGen Vaccines Holding ApS | Company | 50.0% | 50.0% | 2017 |
EXPRES2ION BIOTECHNOLOGIES ApS | Company | 33.3% | 33.3% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EXPRES2ION BIOTECHNOLOGIES ApS
AdaptVac ApS Board members of AdaptVac ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Willem Adriaan De Jongh | Chief Executive Officer | 0 companies |
| Adam Frederik Sander Bertelsen | Management | 0 companies |
| Ali El-Salanti | Board of Directors | 0 companies |
| Jacob Hjulmand | Board of Directors | 0 companies |
| Allan Rosetzsky | Board of Directors | 0 companies |
| Steen Søren Klysner | Chairman | 0 companies |
| Bent Ulrich Frandsen | Board of Directors | 0 companies |
| Morten Agertoug Nielsen | Chairman | 0 companies |